Main Article Content
Akt/GSK3β, ApoE-deficient, Bcl-3, dyslipidemia comorbidity, imiquimod, psoriasis
Background: Psoriasis is considered as an inflammatory skin disease accompanied by dyslipidemia comorbidity. B-cell leukemia-3 (Bcl-3) belongs to IκB (inhibitor of nuclear factor kappa B [NF-κB]) family, and regulates inflammatory response through associating with NF-κB. The role of Bcl-3 in psoriasis was investigated in this study.
Methods: Apolipoprotein E (ApoE)-deficient mice were treated with imiquimod to induce psoriasis and dyslipidemia. Mice were injected intradermally in the back with lentiviral particles encoding Bcl-3 small hairpin RNA (shRNA). Hematoxylin and eosin were used to detect pathological characteristics. The blood lipid levels were determined by automatic biochemical analyzer, and inflammation was assessed by enzyme-linked-immunosorbent serologic assay and real-time quantitative reverse transcription polymerase chain reaction.
Results: Bcl-3 was elevated in imiquimod-induced ApoE-deficient mice. Injection with lentiviral particles encoding Bcl-3 shRNA reduced Psoriasis area and severity index (PASI) score in ApoE-deficient psoriatic mice. Knockdown of Bcl-3 also ameliorated imiquimod-induced psoriasiform skin lesions in ApoE-deficient mice. Moreover, loss of Bcl-3 enhanced expression of loricrin, an epidermal barrier protein, reduced expression of proliferating cell nuclear antigen (PCNA) and lectin-like oxidized LDL (oxLDL) receptor-1 (LOX-1) in imiquimod-induced ApoE-deficient mice. The enhanced levels of blood lipid in ApoE-deficient mice were attenuated by silencing of Bcl-3 with increase of high-density lipoprotein, and reduction of total cholesterol, triglycerides, and low-density lipoprotein cholesterol. Knockdown of Bcl-3 attenuated imiquimod-induced decrease of transforming growth factor beta (TGF-β), and increase of Interleukin (IL)-17A, IL-23, IL-6, and tumor necrosis factor-α (TNF-α) in ApoE-deficient mice. Protein expression of phospho-Akt (p-Akt) and p-GSK3β in ApoE-deficient psoriatic mice was decreased by silencing of Bcl-3.
Conclusion: Loss of Bcl-3 exerted anti-inflammatory effect on psoriasis and dyslipidemia comorbidity through inactivation of Akt/GSK3β pathway.
2. Mikhaylov D, Hashim PW, Nektalova T, Goldenberg G. Systemic psoriasis therapies and comorbid disease in patients with psoriasis: A review of potential risks and benefits. J Clin Aesthet Dermatol. 2019;12(6):46–54. Epub 2019 Jun 1. PMid: 31360288; PMCID: PMC6624011.
3. Katsimbri P, Korakas E, Kountouri A, Ikonomidis I, Tsougos E, Vlachos D, et al. The effect of antioxidant and anti--inflammatory capacity of diet on psoriasis and psoriatic-arthritis phenotype: Nutrition as therapeutic tool? Antioxidants (Basel). 2021; 10(2): 157. 10.3390/antiox10020157
4. Coumbe AG, Pritzker MR, Duprez DA. Cardiovascular risk and psoriasis: Beyond the traditional risk factors. Am J Med. 2014; 127(1): 12–8. 10.1016/j.amjmed.2013.08.013
5. Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediat Inflamm. 2007;2007:78454. 10.1155/2007/78454
6. Xie X, Zhang L, Lin Y, Wang Y, Liu W, Li X. Imiquimod-induced ApoE-deficient mice might be a composite animal model for the study of psoriasis and dyslipideamia comorbidity. J Dermatol Sci. 2017; 88(1):20-28. 10.1016/j.jdermsci.2017.05.003
7. Kaštelan M, Massari LP, Brajac I. The role of bcl-2 family proteins in psoriasis. Liječ Vjesn. 2010;132(1–2):31–3. Croatian. PMid: 20359157.
8. Rückert R, Lindner G, Bulfone-Paus S, Paus R. High-dose proinflammatory cytokines induce apoptosis of hair bulb keratinocytes in vivo. Br J Dermatol. 2000;143(5):1036–9. 10.1046/j.1365-2133.2000.03784.x
9. Chang T-P, Vancurova I. Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma. Biochim Biophys Acta. 2014;1843(11):2620–30. 10.1016/j.bbamcr.2014.07.012
10. Song L, Wörmann S, Ai J, Neuhöfer P, Lesina M, Diakopoulos N, et al. BCL3 reduces the sterile inflammatory response in pancreatic and biliary tissues. Gastroenterology. 2015; 150(2):499-512. 10.1053/j.gastro.2015.10.017
11. Tohyama M, Shirakata Y, Hanakawa Y, Dai X, Shiraishi K, Murakami M, et al. Bcl-3 induced by IL-22 via STAT3 activation acts as a potentiator of psoriasis-related gene expression in epidermal keratinocytes. Eur J Immunol. 2018;48(1):168–79. 10.1002/eji.201747017
12. Miao L, Yin R-X, Pan S-L, Yang S, Yang D-Z, Lin W-X. BCL3-PVRL2-TOMM40 SNPs, gene–gene and gene–environment interactions on dyslipidemia. Sci Rep. 2018;8(1):6189. 10.1038/s41598-018-24432-w
13. Xie X, Zhang L, Li X, Liu W, Wang P, Lin Y, et al. Liangxue jiedu formula improves psoriasis and dyslipidemia comorbidity via PI3K/Akt/mTOR pathway. Front Pharmacol. 2021;12:591608. 10.3389/fphar.2021.591608
14. Koçak M, Bozdogan O, Erkek E, Atasoy P, Birol A. Examination of Bcl-2, Bcl-X and Bax protein expression in psoriasis. Int J Dermatol. 2003;42:789–93. 10.1046/j.1365-4362.2003.01821.x
15. Gehrke N, Wörns M, Huber Y, Hess M, Straub B, Hövelmeyer N, et al. Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors. J Hepatol. 2016; 65(6):1188-1197. 10.1016/j.jhep.2016.06.026
16. Shih C-M, Huang C-Y, Wang K-H, Huang C-Y, Wei P-L, Chang Y-J, et al. Oxidized low-density lipoprotein-deteriorated psoriasis is associated with the upregulation of Lox-1 receptor and Il-23 expression in vivo and in vitro. Int J Mol Sci. 2018;19(9):2610. 10.3390/ijms19092610
17. Meng Y, Wang M, Xie X, Di T, Zhao J, Lin Y, et al. Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells. Int J Mol Med. 2017;39(5):1101–10. 10.3892/ijmm.2017.2930
18. Kim B, Howell M, Guttman-Yassky E, Guttman E, Gilleaudeau P, Cardinale I, et al. TNF downregulates filaggrin and loricrin through c-Jun N-terminal kinase: Role for TNF-antagonists to improve skin barrier. J Invest Dermatol. 2011;131:1272–9. 10.1038/jid.2011.24
19. Elloso MM, Gomez-Angelats M, Fourie AM. Targeting the Th17 pathway in psoriasis. J Leukoc Biol. 2012;92(6):1187–97. 10.1189/jlb.0212101
20. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Ann Rev Immunol. 2014;32:227–55. 10.1146/annurev-immunol-032713-120225
21. Li Y, Schwabe R, Seimon T, Yao P, Gerbod-Giannone M-C, Tall A, et al. Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-α and Interleukin-6: Model of NF-κB-and MAP kinase-dependent inflammation in advanced atherosclerosis. J Biol Chem. 2005;280:21763–72. 10.1074/jbc.M501759200
22. Han G, Williams CA, Salter K, Garl PJ, Li AG, Wang X-J. A role for TGFβ signaling in the pathogenesis of psoriasis. J Invest Dermatol. 2010;130(2):371–7. 10.1038/jid.2009.252
23. Tassi I, Rikhi N, Claudio E, Wang H, Tang W, Ha Hl, et al. The NF-κB regulator Bcl-3 modulates inflammation during contact hypersensitivity reactions in radioresistant cells. Eur J Immunol. 2015;45(4):1059–68. 10.1002/eji.201444994
24. Chen X, Cao X, Sun X, Lei R, Chen P, Zhao Y, et al. Bcl-3 regulates TGFβ signaling by stabilizing Smad3 during breast cancer pulmonary metastasis. Cell Death Dis. 2016;7(12):e2508. 10.1038/cddis.2016.405
25. Jin Qiu YZ, Xie M. Chrysotoxine attenuates sevoflurane-induced neurotoxicity in vitro via regulating PI3K/AKT/GSK pathway. Signa Vitae. 2021;17(4):185–91. 10.22514/sv.2021.107
26. Buerger C. Epidermal mTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target. Front Immunol. 2018;9:2786. 10.3389/fimmu.2018.02786
27. Bürger C, Shirsath N, Lang V, Diehl S, Kaufmann R, Weigert A, et al. Blocking mTOR signalling with rapamycin ameliorates imiquimod-induced psoriasis in mice. Acta Dermatol Venereol. 2017; 97(9):1087-1094. 10.2340/00015555-2724
28. Urban BC, Collard TJ, Eagle CJ, Southern SL, Greenhough A, Hamdollah-Zadeh M, et al. BCL-3 expression promotes colorectal tumorigenesis through activation of AKT-signalling. Gut. 2016;65(7):1151–64. 10.1136/gutjnl-2014-308270
29. Wang VY-F, Li Y, Kim D, Zhong X, Du Q, Ghassemian M, et al. Bcl3 phosphorylation by Akt, Erk2, and IKK is required for its transcriptional activity. Mol Cell. 2017;67(3):484–97.e485. 10.1016/j.molcel.2017.06.011
30. Saito K, Saito M, Taniura N, Okuwa T, Ohara Y. Activation of the PI3K–Akt pathway by human T cell leukemia virus type 1 (HTLV-1) oncoprotein Tax increases Bcl3 expression, which is associated with enhanced growth of HTLV-1-infected T cells. Virology. 2010;403(2):173–80. 10.1016/j.virol.2010.04.018